By Gina Lee
Investing.com – China Meheco Co. Ltd. (SS: 600056 ) saw its shares jump over 9% on Tuesday, and more than 50% in the past week. Speculation is growing that the Beijing-based drug maker is Pfizer Inc.'s (NYSE: PFE ) local partner to distribute its COVID-19 treatment Paxlovid.
The company’s shares jumped 9.35% to HK$17.77 ($x) by 12:24 AM ET (5:24 AM GMT), after rallying by the 10% daily limit for four consecutive days. This is a big turnaround for the shares, which fell to their lowest level since 2014 in February 2022.
The state-owned company warned of uncertainties of the deal with “a certain multinational drug maker” in a statement on Monday, which did not mention Pfizer by name. Contribution to earnings would be small, and even if the deal goes smoothly, “the usage and sales of the drug may depend on factors such as virus control situation,” the statement added.
China’s National Medical Products Administration conditionally approved Paxlovid in February, the first foreign pharmaceutical product endorsed for Covid-19 in the country. The drug is approved to treat adults who have mild to moderate COVID-19 with a high risk of progressing to a severe condition.
With China Meheco the sole drug company overseen by the central government, investors are increasing their bets that the company will be the local distributor.
Add Chart to Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
- Enrich the conversation
- Stay focused and on track. Only post material that’s relevant to the topic being discussed.
- Be respectful. Even negative opinions can be framed positively and diplomatically.
- Use standard writing style. Include punctuation and upper and lower cases.
- NOTE: Spam and/or promotional messages and links within a comment will be removed
- Avoid profanity, slander or personal attacks directed at an author or another user.
- Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
- Only English comments will be allowed.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.